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Summarv 
In the course of investigat.ing the binding of inipra- 
mine to soluble cellular fractions from brain and 
leukocytes usinq eauilibrium dialysis, an artifactual 
binding component was produced. On Scatchard and 
double-reciprocal plots of the data, the component 
appeared as a homogenous population of sites displaying 
a binding affinity of 170 nM. The obtained pattern of 
biphasic interaction bore a marked resemblance to 
reported Scatchard plots representing the interaction 
of drugs with bovine serum albumin, and depicting two 
components of widely differing bindinq a.ffinity and 
capacity. The artifact occurred when solutions were 
transferred after dialysis and before auantitation to 
3 
'ntermediate containers, and resulted from binding of 
H-imipramine to the walls of these containers. The 
latter interaction decreased the concentration Of 
radiolabeled drug in the dialysate but not in the 
dialyzed solution, and thus mimicked increased imipra- 
mine binding to the biological material under study. 
The effect was particularly pronounced at low drug 
concentrations, and was prevented by the presence of 
either proteinaceous material, or of an excess of 
another basic compound such as methadone. The concen- 
tration dependence of the phenomenon led to it-s appear- 
ance as a discrete binding component. The artifact was 
eliminated either by applying an appropriate correction 
factor, or by transferring the dialyzed solutions 
directly into scintillation vials for counting. 
Earlier work in this laboratory has provided evj.dence for the 
active transport of drugs, with the structural feature of basic 
amines, in leukocytes (1,2) and synaptosomes (3), and for the 
mediated transport of similar drugs in the isolated retina (4). 
The evidence included saturable transport components, competi- 
tive inhibition by structural analoques, specific dependence on 
metabolic energy and temperature, and a demonstration of trans- 
acceleration. In order to assess the possible contribution of 
intracellular binding to the observed cellular accumulation of 
basic drugs, e.g., benzomorphans, tricyclic antidepressants and 
0024-3205183 $3.00 + .OO 
Copyright (c) 1983 Pergamon Press Ltd. 
132 Drug-Protein Binding Vol. 33, No. 2, 1983 
methadone, we have investigated their binding in soluble cellu- 
lar fractions from brain and leukocytes using equilibrium 
dialvsis. The bindinq data were evaluated on double reciprocal 
(5) and Scatchard (6) plots. In this report we describe experi- 
mental conditions for equilibrium dialvsis under which a well 
defined but artifactual bindinq component for imipramine was 
generated, mimicking drug-protein interaction of apparent high 
affinity. In addition to imipramine other basic compounds, such 
as methadone, have the potential to display this misleading 
phenomenon. 
Materials and Methods 
[2,4,6,8-3H]-Imipramine. HCl and [Methylene-14C]-Imipra- 
mine.HCl were purchased from New England Nuclear, Boston, MA, 
and Amersham/Searle, Arlington Heights, IL, respectively. The 
radiochemical purity of these compounds was greater than 98%, as 
confirmed in our laboratory by thin-layer chromatography. 
Unlabeled imipramine and methadone were obtained throuqh the 
Drug Abuse Basic Research Program at the (Jniversity of Michiqan. 
Bovine serum albumin, fraction V and crvstalline, were obtained 
from Sigma Chemical Company, St. Louis, MO. All other chemicals 
were of reagent qrade. Karush-type dialvsis chambers (7) were 
purchased from Bellco, Vinland, FJJ. Dialysis tubinq with flat 
diameters of 9 mm and 24 mm was purchased from the Films and 
Packing Division of Union Carbide Corporation, Chicago, IL. The 
buffer medium used throuahout this work had the following compo- 
sition (mM) : NaCl, 123; KCl, 5; MgS0 4, 1.5; Na2HPC4, 16. The 
pH was adjusted to 7.4 with HCl. 
Membranes for dialysis were prepared by cutting the dialys- 
is tubing open to yield single-laver rectangles of 4 cm x 2.4 
cm. The cut pieces were repeatedly washed and soaked overnight 
in distilled water at 4'. The membranes were then rinsed again 
and were left standing in distilled water until assemblv into 
the Karush-type glass dialysis chamber. In some experiments 
dialysis was carried out in bags, after rinsing the dialysis 
tubing as described above. 
A soluble, predominantly cytoplasmic, fraction from rat 
brain was prepared as follows: male Sprague-Dawley rats weigh- 
ing 200-300 g were lightly anesthetized with diethyl ether, 
decapitated, and the heads placed on ice. All subsequent steps 
were carried out at 4O. The brain was excised, and the cerebrum 
was dissected and cleaned of meninges. The cerebra from 2-3 
rats were disrupted in a Potter-Elvehjem type homogenizer with 
10 volumes of ice-cold buffer using eight full strokes of a 
Teflon pestle at 500 rpm. The homogenate was centrifuqed at 
25,000 x g for 20 min, and the supernatant was collected. The 
latter was then centrifuged at 105,000 x g for 60 min, and the 
supernatant diluted with buffer to the protein concentration 
desired. Protein was determined according to Lowry et al. (8) 
with crystalline bovine serum albumin as standard. 
Formation of rat polymorphonuclear leukocytes was i duced 
bv the intraperitoneal injection of sodium ' A caseinate . 
1E.I. Cullen, C.J. Spears, and F. Medzihradsky, unpublished 
observations. 
Vol. 33, No. 2, 1983 Drug-Protein Binding 133 
soluble cellular fraction was prepared by thrice freezing in dry 
ice-acetone (-70°) and thawing to room temperature. Following 
centrifugations as described above at 25,000 x q and 105,000 x q 
for 20 min and 60 min, respectively, equilibrium dialysis was 
carried out with the resulting supernatant. 
The general protocol for eauilibrium dialysis was as fol- 
lows: 1.0 ml of the freshly prepared soluble fraction from 
brain or leukocytes was pipetted into one side of the Karush 
chamber or into a dialysis bag of 90 mm flat diameter. To the 
other side of the Karush assembly or the outside of the dialysis 
hag were added 3 Rm&oi42 "l! 
respectively, of the buffer contain- 
ing 0.2 PCi of C-imipramine and different concentrations 
of the unlabeled drug. In experiments investiqatinq competitive 
drug interactions that solution also contained 1 mV unlabeled 
d,l-methadone. The chambers were placed on a Rotating Mixer (9) 
designed to accept the Karush-type dialvsis chambers. Dialysis 
was carried out at 3 rpm for 18 hours at 4", a time period shown 
to be sufficient to reach equilibrium. The solutions from each 
side of the apparatus were then transferred into separate poly- 
propylene tubes from which aliquots were pipetted into scintilla- 
tion vials for counting. The radioactivity in the dialysate 
represented free drug, and the concentration of bound drug was 
calculated from the difference between the radioactivity measur- 
ed in the two dialysis compartments. Apparent KD 's were calcu- 
lated from the binding curves by the method of least squares. 
The contributions from the separate bindinq components were 
calculated according to Neal (lo), and were also analyzed using 
a nonlinear least squares regression computer program (11). 
Results and Discussion 
Data of initial experiments depicted two binding components 
for imipramine in soluble fractions from brain and leukocytes. 
Scatchard plots were biphasic, showing in both fractions two 
distinct, homogeneous populations of binding sites with apparent 
K 's of 24 FM (brain) and 44 PM (leukocytes), in addition to a 
b!?ndinq component of much lower affinity and considerably higher 
binding capacity (Fig. 1, left graph). The resolution of the 
data, considering the mutual interference of the components 
(lo), markedly altered the values of the apparent binding 
constants for the high affinity component, while not affecting 
low affinity binding (Table 1). 
The patterns obtained were markedly similar to published 
Scatchard plots of drug binding to bovine serum albumin. In the 
example shown here (Fig. 1. inset) salicylate was bound to 2 
classes of sites with K 's of 40 PM and 6.6 mM (12). Further- 
more, it was of interes P to note the similarly high affinity of 
apparent intracellular imipramine binding and of desipramine and 
methadone transport described in leukocytes (1,2) and synapto- 
somes (3). 
Our suspicion about the validity of these results was 
raised by the observation that heat treatment had little effect 
on the high affinity binding component described above. The 
soluble fraction from brain was exposed to 70" for 20 min and 
then centrifuged to remove the precipitate. Equilibrium dialys- 
is with the heated material yielded a double-reciprocal plot 
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depicting a high affinity K still in the submicromolar range 
(Fig. 1, right graph). Ferther investigation identified a 
procedural step as the source for the obtained biphasic drug 
binding. As described above, followinq equilibrium dialysis the 
solutions from each compartment were transferred into test tubes 
prior to the quantitative removal of aliquots for 1~i~qui.d scin- 
tillation counting. In samples without protein, a concentration 
dependent interaction between imipramine and the tube material 
occurred (Fiq. 2). 
1 FIG. 
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Equilibrium dialysis with soluble tissue fractions. In 
all the experiments shown in this fiqure, equilibrium 
dialysis was terminated by transferring the solutions 
to polypropylene tubes before aliquots were pipetted 
into scintillation vials for quantitation of radioac- 
tivity. The results shown were replicated at least 3 
times. The standard deviation around the calculated 
mean of the affinity constants was 11%. The Scatchard 
plots (left graph) depict data obtained from equili- 
brium dialysis performed as describ? in the text using 
either Karush dialysis chambers, [ HI-imipramine, and 
soluble, I’d_~~_“i’~~p~a~~~ata~~a~o~~~~~ ~~~;;~icntg ;$z;xyfz 
bags, 
from leukocytes (0). 'The inset depicts a Scatchard 
plot of salicylate binding to bovine serum albumin in 
phosphate buffer at pH 7.4 (reproduced by permission 
from reference 12). The double-reciprocal plot (right 
graph) represeTs, results of equilibrium dialysis 
performed with H-imipramine in Karush dialysis cham- 
bers using the soluble brain fraction which had been 
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As a consequence, the difference between the radioactivity 
from the samples with and without protein was larqe at lower 
drug concentrations (Fig. 2, inset). The effect decreased the 
free imipramine concentration and, thus, mimicked druq bindinq 
to the biological material under study. This artifactual 
binding component was reflected on both Scatchard and double 
reciprocal plots (Fig. 1). 
TABLE 1 
Apparent and corrected values of the hindinq constants 






(0) (nmole/mg pr) ( ii Ml (nmole/ms pr) 
Soluble fraction from brain 
A. High 
affinity 
component 24 1.6 0.14 0.60 
B. Low 
affinity 
comoonent 2400 100 2415 99.4 
Soluble fraction from leukocvtes 
A. High 
affinity 
component 51 2.7 0.15 0.89 
B. Low 
affinity 
component 5650 140 5686 139 
The apparent values were obtained from the 
respective binding curves. The corrections were 
implemented according to Neal (IO), considerinq the 
mutual interference of the two binding components. 
(Bmax = maximal binding: pr = protein) 
The interaction between drug and tube material was prevent- 
ed by proteinaceous material. Both soluble cellular fractions 
and bovine serum albumin were effective, and resulted in differ- 
ent amounts of recoverable radioactivity in the two dialysis 
compartments, i.e., samp es 
5 
with and without protein (Table 2 
and Fig. 2). Binding of H-imipramine to the tube wall occurred 
rapidly, and long-range incubation added little to the initial 
effect (Table 2). The phenomenon was observed with three 
different types of tube surfaces: polypropylene, glass that had 
been acid washed, and glass initially siliconized according to a 
procedure described previously (13). 




H-imipramine from solutions 
in the presence and absence of protein 
3 
H-Imioramine Recovered radioactivitv 
Experimental 
conditions 
recovered per (+ protein) ’ 
aliauot Recovered radioactivity 
(cpm) (- protein) 
Polypropvlene tubes, overnight incubation 
Buffer alone 2334 
0.2 mq/ml SBF 2511 
0.6 mq/ml SBF 2526 
1.0 mq/ml SBF 2528 
Acid washed tubes, overniqht. incubation 
Buffer alone 2369 
0.2 mq/ml SBF 2560 
0.6 mq/ml SBF 2531 
1.0 mq/ml SBF 2522 
Siliconized glass tubes, overnight incubation 
Buffer alone 2356 
0.2 mq/ml SBF 2489 
0.6 mq/ml SBF 2487 
1.0 mg/ml SBF 2533 
Polypropylene tubes, 15 min incubation 
Buffer alone 3731 
4.0 mq/ml BSA 3963 
Polypropylene tubes, overniqht incubation 
Buffer alone 3654 

















Mix directly in counting vial, 15 min incubation 
Buffer alone 4024 --- 
4.0 mq/ml BSA 4034 1.002 
Mix direct1.y in counting vial, overnight incubation 
Buffer alone 3994 --- 
4.0 mq/ml BSA 4029 1.009 
Solutions were mixed in the containers indicated in 
order to give a final concentration of 5 UM imipramine 
and the protein concentrations shown (BSA = bovine 
serum albumin: SBF = soluble brain fraction). The 
final volume in the mixing tubes was 1 ml. Three 100 
LJl aliquots were taken from each tube for liquid 
scintillation counting. The incubation in counting 
vials was carried out with 100 ~1 volumes. The incuba- 
tions were performed at 4'. Each value shown repre- 
sents the mean obtained from 3 tubes or vials. 






-70 -60 -50 -40 
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H-imipramine binding to test tube walls. To a series 
of polypropylene tubes were added 200 ~1. huffer (0, or 
200 ~1 of 8 mg/ml BSA (e), followed by 160 ~1 of an 
appropriate solution of unlabeled imipramine to yield 
the in 
d+ 
'cated final concentrations, and 40 pl of 1 
uCi/ml H-imipramine. The tubes were then incubated at 
room temperature for 2 hours. At that time, three 120 
~1 aliquots were removed from each tube for the deter- 
mination of radioactivitv. Plotted is the measured 
radioactivity per aliquot against the logarithm of the 
imipramine concentration. Each point is the mean of 
triplicate determinations. The average standard 
deviation around the mean was 1.6%. The inset shows 
results of an experiment performed exactly as described 
above except that soluble brain fraction, at 2 mg 
protein/ml, was used instead of BSA. Plotted are the 
ratio of radioactivities recovered from the tubes with 
and without the biological material, against the 
logarithm of the initial imipramine concentration. 
Considering that imipramine and methadone were competitive 
structural analoques in the active transport system described in 
leukocytes (1,2), it was our original aim to investigate whether 
competitive inhihition could be demonstrated during the course 
of drug binding to soluble cellular fractions. Indeed, in 
initial experiments the double-reciprocal plots of imipramine 
binding in the presence of excess methadone were monophasic, 
suggesting the inhibition of the apparent high affinity binding 
component (Fig. 3, left graph). 
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Double-reciprocal plot of 
3 
H-imipramine binding: 
effect of methadone, and correction of artifact. 
Equilibrium dialysi3s was performed with the soluble 
brain fraction and H-imipramine in the Karush dialysis 
chambers in the presence (A) or absence (0) of 500 PM 
methadone (left graph). After dialysis, the solutions 
were transferred to polypropylene tubes before aliquots 
were taken for the determination of r?dioactivitv. 
Shown in the right graph are the data for H-imipramine 
binding obtained in the absence of methadone before (0) 
and after correction (m) for the extent of drug 
interaction with container material, considering the 
findings depicted in Fig. 2. 
However, appropriate control experiments revealed, as in 
the experiments without competitive drug interaction, the error 
of that conclusion. Aliquots of either soluble cellular mater- 
ial, bovine serum albumin, or buffer alone were added to polv- 
propylene tubes with or without a solution of methadone that 
yielded a final CT centration of 750 uM. After the addition of 
equal amounts of H-imipramine, the tubes were incubated over- 
night at 4O. Aliquots from these tubes were then pipetted into 
scintillation vials for counting. At 5 PM imipramine, the data 
indicated a 7.4% difference in counts between the samples 
containing proteinaceous material and buffer alone. That 
difference was reduced to 1.8% in the presence of 750 PM metha- 
done. When 400 UM unlabeled imipramine was initially present, 
the maximal difference in counts was reduced to 1.2% and 750 PM 
methadone had little additional effect. If the components of 
the above incubation medium were mixed directly in the scintil- 
lation vials in which they were subsequently counted, there was 
no difference in counts between samples with and without pro- 
tein. 
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The artificial binding component was also eliqnated by 
computation. The results of equilibrium dialysis of H-imipra- 
mine with soluble cellular fractions were corrected by a factor 
representing the difference in recoverable radioactivity between 
samples without and with protein (Fiq. 2). Double-reciprocal 
plots of such revised binding data depicted a single binding 
component (Fig. 3, 
capacity, 
right graph) of low affinity rd very high 
indistinguishable from that obtained for H-imipramine 
bindinq in the presence of excess methadone (Fiq. 3, left 
graph) . Corresponding Scatchard plots (not shown) indicated the 
same result. On both of these plots the pr?viously seen hiqh 
affinity apparent binding component for H-imipramine was 
absent. A one component non-saturable model was used to calcu- 
late empirical binding constants relating bound (nmol/mq pro- 
tein) to free (nmole/ml) imipramine. The values obtained for 
the methadone inhibited group (Fig. 3, left graph) and the 
bindinq data corrected by computation (Fiq. 3, right graph) were 
indistinguishable at 0.0355 f 0.0003 ml/mq protein. 
Although this work was limited to the use of imipramine and 
methadone, the nature of the artifact implies that it can occur 
with any compound capable of binding to plastic material or to 
qlass under similar circumstances. Significant binding to 
container walls has been reported for methotrexate, promazine, 
thiopental and other compounds (14-16). The interaction of 
basic drugs with bindinq sites on glass-fiber filters has been 
reported (17,181 and was in the focus of a recent controversy on 
the biological specificity of the observed phenomenon (19). The 
appearance of the artifactual binding component, described here, 
as a distinct population of sites with significant binding 
affinity carries an impressive potential for misleading interpre- 
tations in assessing drug-protein interactions by the widespread 
use of equilibrium dialysis. 
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